The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence

Pharmacology Biochemistry and Behavior

Volumn 53, Issue 4, 1996, Pages 791-797

  Popik, Piotr ^a,b   Skolnick, Phil ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Addiction; Dependence; Glycine; Memantine; Morphine; NMDA receptor antagonists; NPC 17742; Withdrawal

Indexed keywords

2 AMINO 4,5 (1,2 CYCLOHEXYL) 7 PHOSPHONOHEPTANOIC ACID; GLYCINE; MEMANTINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG ANTAGONISM; INTRAPERITONEAL DRUG ADMINISTRATION; JUMPING; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 0029930965     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02163-9     Document Type: Article

References (57)

1. Akaoka, H.; Aston-Jones, G. Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J. Neurosci. 11:3830-3839; 1991.
2. Ascher, P.; Nowak, L. Electrophysiological studies of NMDA receptors. Trends Neurosci. 10:284-287; 1987.
3. Ben-Eliyahu, S.; Marek, P.; Vaccarino, A. L.; Mogil, J. S.; Sternberg, W. F.; Liebeskind, J. C. The NMDA receptor antagonist MK-801 prevents long-lasting nonassociative morphine tolerance in the rat. Brain Res. 575:304-308; 1992.
4. Bormann, J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166: 591-592; 1989.
5. Bubser, M.; Keseberg, U.; Notz, P. K.; Schmidt, W. J. Differential behavioural and neurochemical effects of competitive and noncompetitive NMDA receptor antagonists in rats. Eur. J. Pharmacol. 229:75-82; 1992.
6. Cappendijk, S. L.; de Vries, R.; Dzoljic, M. R. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur. Neuropsychopharmacol. 3:111-116; 1993.
7. Chen, H. S.; Pellegrini, J. W.; Aggarwal, S. K.; Lei, S. Z.; Warach, S.; Jensen, F. E.; Lipton, S. A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:4427-4436; 1992.
8. Contreras, P.C. D-Serine antagonized phencyclidine and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology 29:291-293; 1990.
9. Danysz, W.; Wroblewski, J. T.; Costa, E. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 27:653-656; 1988.
10. Ditzler, K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double blind, placebo controlled trial. Arzneim.-Forsch. Drug. Res. 41:773-780; 1991.
11. Elliott, K.; Minami, N.; Kolesnikov, Y. A.; Pasternak, G. W.; Inturrisi, C. E. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, ng-nitro-l-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 56:69-75; 1994.
12. Evoniuk, G. E.; Hertzman, R. P.; Skolnick, P. A rapid method for evaluating the behavioral effects of phencyclidine-like dissociative anesthetics in mice. Psychopharmacology 150:125-128; 1991.
13. Ferkany, J. W.; Hamilton, G. S.; Patch, R. J.; Huang, Z.; Borosky, S. A.; Bednar, D. L.; Jones, B. E.; Zubrowski, R.; Willetts, J.; Karbon, E. W. Pharmacological profile of NPC 17742 [2R,4R,5S-(2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid)], a potent, selective and competitive N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Ther. 264:256-264; 1993.
14. Ginski, M. J.; Witkin, J. M. Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology 114:573-582; 1994.
15. Greenamyre, J. T.; O'Brien, C. F. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48: 977-981; 1991.
16. Greenamyre, J. T.; Young, A. B. Excitatory amino acids and Alzheimer's disease. Neurobiol. Aging 10:593-602; 1989.
17. Handelmann, G. E.; Contreras, P. C.; O'Donohue, T. L. Selective memory impairment by phencyclidine in rats. Eur. J. Pharmacol. 140:69-73; 1987.
18. Higgins, G. A.; Nguyen, P.; Sellers, E. M. The NMDA antagonist dizocilpine (MK-801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci. 50:PL167-PL172; 1992.
19. Hiramatsu, M.; Cho, A. K.; Nabeshima, T. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol. 166:359-366; 1989.
20. Jaffe, J. H. Drug addiction and drug abuse. In: Gilman, A. G.; Goodman, L. S.; Rail, T. W.; Murad, F., eds. Goodman and Gilman's The pharmacological basis of therapeutics. New York: Macmillan Publishing Company; 1985:532-588.
21. 3H]MK-801 binding: Evidence for access to closed and open N-methyl-D-aspartate receptor channels. Mol. Pharmacol. 35:387-393; 1989.
22. Kesner, R. P.; Priano, D. J.; DeWitt, J. R. Time-dependent distribution of morphine tolerance by electroconvulsive shock and frontal cortical stimulation. Science 194:1079-1081; 1976.
23. Kleckner, N. W.; Dingledine, R. Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science 241:835-837; 1988.
24. Kolesnikov, Y. A.; Maccecchini, M.-L.; Pasternak, G. W. 1-Aminocyclopropanecarboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 55:1393-1398; 1994.
25. Kornhuber, J.; Bormann, J.; Hubers, M.; Rusche, K.; Riederer, P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. Eur. J. Pharmacol. 206:297-300; 1991.
26. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166: 589-590; 1989.
27. Koyuncuoglu, H.; Saydam, B. The treatment of heroin addicts with dextromethorphan. A double-blind comparison of dextromethorphan with chloropromazine. Int. J. Clin. Pharmacol. Ther. Toxicol. 28:147-152; 1990.
28. Lotsof, H. S. Ibogaine in the treatment of chemical dependency disorders: Clinical perspectives. Bull. Multidisc. Assoc. Psychedel. Stud. 5(3):16-27; 1995.
29. Lutfy, K.; Hurlbut, D. E.; Weber, E. Blockade of morphine-induced analgesia and tolerance in mice by MK-801. Brain Res. 616:83-88; 1993.
30. Moryl, E.; Danysz, W.; Quack, G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 72:394-397; 1993.
31. Muir, K. W.; Grosset, D. G.; Gamzu, E.; Lees, K. R. Pharmacological effects of the noncompetitive NMDA antagonist cns 1102 in normal volunteers. Br. J. Clin. Pharmacol. 38:33-38; 1994.
32. Nowak, L.; Bregestovski, P.; Ascher, P.; Herbet, A.; Prochiantz, A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307:462-465; 1984.
33. Rasmussen, K.; Fuller, R. W.; Stockton, M. E.; Perry, K. W.; Swinford, R. M.; Ornstein, P. L. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol. 197:9-16; 1991.
34. Riederer, P.; Lange, K. W.; Kornhuber, J.; Danielczyk, W. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338:1022-1023; 1991.
35. Rossetti, Z. L.; Hmaidan, Y.; Gessa, G. L. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol. 221:227-234; 1992.
36. Saelens, J. K.; Granat, F. R.; Sawyer, W. K. The mouse jumping test - a simple screening method to estimate the physical dependence capacity of analgesics. Arch. Int. Pharmacodyn. 190:213-218; 1971.
37. Salt, T. E. Modulation of NMDA receptor-mediated responses by glycine and D-serine in the rat thalamus in vivo. Brain Res. 481:403-406; 1989.
38. Sanchez-Ramos, J.; Mash, D. Ibogaine research update: Phase I human study. Multidisc. Assoc. Psychedel. Stud. 4:11; 1994.
39. Sanger, D. J.; Terry, P.; Katz, J. L. Memantine has phencyclidine-like but not cocaine-like discriminative stimulus effects in rats. Behav. Pharmacol. 3:265-268; 1992.
40. Shapiro, M. L.; Caramanos, Z. NMDA antagonist MK-801 impairs acquisition but not performance of spatial working and reference memory. Psychobiology 18:231-243; 1990.
41. Sheppard, S. G. A preliminary investigation of ibogaine: Case reports and recommendations for further study. J. Subst. Abuse Treatm. 11:379; 1994.
42. Siegel, S. Evidence from rats that morphine tolerance is a learned response. J. Comp. Physiol. Psychol. 89:498-506; 1975.
43. Siegel, S. Morphine analgesic tolerance: Its situation specificity supports a pavlovian conditioning model. Science 193:323-325; 1976.
44. Sierocińska, J.; Nikolaev, E.; Danysz, W.; Kaczmarek, L. Dextrorphan blocks long-but not short-term memory in a passive avoidance task in rats. Eur. J. Pharmacol. 205:109-111; 1991.
45. Sveinbjornsdottir, S.; Sander, J. W.; Upton, D.; Thompson, P. J.; Patsalos, P. N.; Hirt, D.; Emre, M.; Lowe, D.; Duncan, J. S. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. 16:165-174; 1993.
46. Tanganelli, S.; Antonelli, T.; Morari, M.; Bianchi, C.; Beanin, L. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci. Lett. 122:270-272; 1991.
47. Thomson, A. M.; Walker, V. E.; Flynn, D. M. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature 338:422-424; 1989.
48. Tiseo, P. J.; Cheng, J.; Pasternak, G. W.; Inturrisi, C. E. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: Assessment of opioid receptor changes. J. Pharmacol. Exp. Ther. 268:195-201; 1994.
49. Tiseo, P. J.; Inturrisi, C. E. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264:1090-1096; 1993.
50. Tonkiss, J.; Morris, R. G.; Rawlins, J. N. Intra-ventricular infusion of the NMDA antagonist AP5 impairs performance on a nonspatial operant DRL task in the rat. Exp. Brain Res. 73:181-188; 1988.
51. Toth, E. Studies on the inhibition of phencyclidine - induced hyperactivity by glycine in mice. In: Domino, E.; Kamenka, J., eds. Sigma and phencyclidine-like compounds as molecular probes in biology. Ann Arbor: NPP Books; 1988:483-491.
52. Toth, E.; Lajtha, A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem. Res. 11:393-400; 1986.
53. Trujillo, K. A.; Akil, H. Opiate tolerance and dependence: Recent findings and synthesis. New Biol. 3:915-923; 1991.
54. Trujillo, K. A.; Akil, H. The NMDA receptor antagonist MK-801 increases morphine catalepsy and lethality. Pharmacol. Biochem. Behav. 38:673-675; 1991.
55. Trujillo, K. A.; Akil, H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85-87; 1991.
56. Trullas, R.; Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185:1-10; 1990.
57. Wolfer, D. P.; Lipp, H.-P. A new computer program for detailed off-line analysis of swimming navigation in the Morris water maze. J. Neurosci. Methods 41:65-74; 1992.